Halozyme(HALO) Prnewswire·2025-02-04 13:30Company Overview - Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on improving patient experiences and outcomes through innovative solutions [3] - The company is known for its ENHANZE® drug delivery technology, which utilizes the proprietary enzyme rHuPH20 to facilitate subcutaneous delivery of drugs and fluids [3] - Halozyme has impacted over one million patients through its technology, which is used in nine commercialized products across more than 100 global markets [3] Financial Results Announcement - Halozyme will release its fourth quarter and full year 2024 financial and operating results on February 18, 2025, after the market closes [1] - A conference call to discuss these results will take place on the same day at 1:30 p.m. PT/4:30 p.m. ET, with access available via pre-registration [1] Product Development and Partnerships - The company develops, manufactures, and commercializes drug-device combination products, leveraging advanced auto-injector technologies for improved patient convenience and adherence [4] - Halozyme has two proprietary commercial products, Hylenex® and XYOSTED®, and collaborates with several pharmaceutical companies, including Teva Pharmaceuticals and Idorsia Pharmaceuticals, for ongoing product development [4]